Pages that link to "Q33185340"

The following pages link to Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study (Q33185340):

Displaying 49 items.

• Management of sexual dysfunction due to antipsychotic drug therapy (Q24197558) (← links)
• Risperidone versus other atypical antipsychotics for schizophrenia (Q24234950) (← links)
• Amisulpride versus other atypical antipsychotics for schizophrenia (Q24240433) (← links)
• Management of sexual dysfunction due to antipsychotic drug therapy (Q24246362) (← links)
• The use of amisulpride in the treatment of acute psychosis (Q24683055) (← links)
• The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study (Q24800019) (← links)
• Amisulpride: a review of its use in the management of schizophrenia (Q28291252) (← links)
• World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia (Q33223628) (← links)
• World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia (Q33235110) (← links)
• The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study (Q33609974) (← links)
• Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study (Q33879147) (← links)
• Is the PANSS used correctly? a systematic review. (Q33964357) (← links)
• Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study (Q34037969) (← links)
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance (Q34640811) (← links)
• Almost all antipsychotics result in weight gain: a meta-analysis (Q34661499) (← links)
• Safety and tolerability of antipsychotics: focus on amisulpride (Q35026487) (← links)
• Weight gain profiles of new anti-psychotics: public health consequences (Q35198895) (← links)
• Long-acting risperidone: a review of its use in schizophrenia (Q35631406) (← links)
• Switching between second-generation antipsychotics: why and how? (Q36009886) (← links)
• Risperidone: a review (Q36150794) (← links)
• The relationship between patient satisfaction and treatment outcomes in schizophrenia (Q36626251) (← links)
• Adverse effects of atypical antipsychotics in the elderly: a review (Q36677274) (← links)
• Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder (Q36836740) (← links)
• Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal (Q37188995) (← links)
• Practical issues with amisulpride in the management of patients with schizophrenia. (Q37206139) (← links)
• Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features (Q37227479) (← links)
• The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study (Q37352336) (← links)
• Management of patients presenting with acute psychotic episodes of schizophrenia. (Q37423313) (← links)
• Second-generation antipsychotics: are their similarities greater than their differences? (Q38097489) (← links)
• Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity (Q38677949) (← links)
• Quality of life and functioning in first-episode psychosis Chinese patients with different antipsychotic medications. (Q38809849) (← links)
• Update on the management of symptoms in schizophrenia: focus on amisulpride (Q41529086) (← links)
• Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs? (Q43789375) (← links)
• Amisulpride is an "atypical" antipsychotic associated with low weight gain (Q44675344) (← links)
• Amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders (Q46097656) (← links)
• A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study (Q46142676) (← links)
• Development of novel amisulpride-loaded solid self-nanoemulsifying tablets: preparation and pharmacokinetic evaluation in rabbits (Q46357890) (← links)
• The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials. (Q46670479) (← links)
• A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia (Q48381074) (← links)
• Prandial effect on the systemic exposure of amisulpride. (Q51327838) (← links)
• Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. (Q51487515) (← links)
• On the concept of remission in schizophrenia (Q51901729) (← links)
• Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone (Q51968316) (← links)
• The acute and long‐term effectiveness of amisulpride in patients with schizophrenia: results of a 12‐month open‐label prospective follow‐up study (Q60637427) (← links)
• [Sexual behaviour in schizophrenic patients: the impact of antipsychotics] (Q79351323) (← links)
• Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs (Q79744901) (← links)
• Linking the PANSS, BPRS, and CGI: clinical implications (Q79845789) (← links)
• How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials (Q89458401) (← links)
• Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons (Q91790829) (← links)